Find in Library

<i>Background</i>: Since 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic (COVID-19) has caused millions of deaths worldwide and is the second most serious pandemic after the Spanish flu. Despite SARS-CoV-2 infection having a dominant effect on morbidity and life-threatening outcomes, the role of bacterial co-infection in patients with COVID-19 is poorly understood. The present study aimed to verify the existence of bacterial co-infections and their possible role as cofactors worsening COVID-19-related clinical manifestations. <i>Methods</i>: All patients with suspected SARS-CoV-infection, hospitalised in COVID-19 wards at the Sant’Anna University Hospital of Ferrara, were retrospectively included in this single-centre study and their specific bacterial serologies were assessed. Univariate and logistic regression analyses were performed. <i>Results</i>: A total of 1204 individual records were retrieved. Among them, 959 were excluded because of a negative nasopharyngeal swab or missing data; of the eligible 245 patients, 51 were co-infected. Compared to patients with SARS-CoV-2 infection alone, those with <i>Chlamydia pneumoniae</i> or <i>Mycoplasma pneumoniae</i> co-infections had worse respiratory/radiological features and more intensive care unit admissions. However, the co-infection did not result in a higher mortality rate. <i>Conclusions</i>: The present study, comparing clinical, laboratory and radiological findings between patients with COVID-19 vs. those with co-infections (<i>C. pneumoniae</i> or <i>M. pneumoniae</i>) showed that, on admission, these features were worse in co-infected patients, although the mortality rate did not differ between the two groups.